Protecting companies’ IP in the New Global Economic Turmoil

2020年10月13日

We are delighted to be one of the supporting organisations of the “AIDRN Business and Dispute Resolution Webinar Series (2020) – Session 2”.

Details of the event can be found here and from the webpage links below:

English – httpss://aidrn.org/ibdrwebseriess2-ip-en/

Traditional Chinese – httpss://aidrn.org/zh/ibdrwebseriess2-ip-tc/

我們過去活動

Eagle IP Celebrates 20th Anniversary, Reflecting on Two Decades of Excellence

2025年5月21日

Eagle IP is Coming Back to LSPN in Boston!

2025年4月24日

AIPLA Women in IP Global Networking Event in Hong Kong

2025年4月3日

Talk at Hong Kong Christian Service

2024年10月31日

Talk for HKUST Entrepreneurship 101 Training Program

2024年10月31日

IP Training Programme on patent commercialization and technology transfer

2024年10月8日

Recommended Insights

A Detailed Dive into China’s New Patent Term Extension Provisions

2020年12月11日

This article is a part of a larger article that highlights the newest draft implementation rules of the new Chinese Patent Law. This particular article takes a detailed dive into the patent term extension/adjustment provisions. One of the biggest and most exciting provisions in the newly amended patent law is patent term extension for delay […]

Introducing the New USPTO Cancer Moonshot Expedited Examination Pilot Program

2023年1月10日

Starting from February 1, 2023, the USPTO will begin the new Cancer Moonshot Expedited Examination Pilot Program that advances out-of-turn applications that are directed to oncology or smoking cessation. This new program will replace the Cancer Immunotherapy Pilot Program that has been in place since 2016, and covers more technologies than only cancer immunotherapies. Applications […]

AI is magical but NOT magic! Be specific in your AI patents!

2025年1月9日

What is the standard of sufficient disclosure for AI-related patents: A case study in China The rapid growth of AI patent applications present significant challenges to existing patent application and examination practices. One of them is satisfying the requirement for sufficient disclosure. The following case was featured in the 2023 CNIPA Compilation of Key Decisions […]

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

2020年7月14日

This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]